PASITHEA THERAPEUTICS CORP (KTTA)
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
$0.58-0.07%
Close 2026-09-04 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
QuarterlyIQ Insights · KTTA
How strong the business is — where it ranks within its sector on capital efficiency and cash generation, and how well management has been executing.
How management runs the business: capital, margins, balance sheet, and how reliably they guide and deliver.
A guidance track record builds as the company issues and delivers on guidance.
Priorities management has stated in recent disclosures, with status and evidence drawn from earnings calls, filings, and press releases.
Continue advancing PAS-004 clinical trials and medical strategy for NF1 and other indications.
Newly stated in 2026-Q2 with the appointment of a new Chief Medical Officer to lead clinical development and medical strategy for PAS-004. Financials show continued operating losses and negative net income, reflecting ongoing investment in clinical programs. The trajectory is consistent with early-stage clinical development focus but no revenue or profitability improvement yet.
Each factor is a parallel diagnostic with a clear read of what it shows and how names like it have historically fared. Never aggregated into a single score.
Operating income rose in 1 of the last 3 quarter-over-quarter moves. Historically, Health Care names rated neutral grew net income 51% of the time over the next year (vs 41% for the rest of the cohort, n=13363).
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
“Dr. Krishnan will oversee all clinical development and medical strategy as the Company advances PAS-004 through the clinic for NF1.”
Resolve Nasdaq listing deficiencies related to stock price to maintain listing status.
Newly stated in 2026-Q2 with a Nasdaq letter citing failure to meet listing price requirements. The company faces regulatory risk due to low stock price. Financials show ongoing losses and negative cash flow, which may challenge compliance efforts. The trajectory is concerning given the regulatory notice.
“Received letter from Nasdaq regarding failure to satisfy continued listing rule due to closing bid price.”
Control operating losses and negative cash flow while progressing clinical programs.
Stated as a priority in 8 of last 8 quarters. Operating income worsened from negative $3.0M in 2024-Q3 to negative $5.7M in 2026-Q2. Cash from operations remained negative, increasing from $3.1M outflow in 2024-Q3 to $4.7M outflow in 2026-Q2. Management continues to highlight managing losses and cash flow, but financials show increasing operating losses and cash burn, indicating limited progress on cost containment.
“Operating income was negative $5.7M and cash from operations negative $4.7M.”
“Operating income was negative $4.9M and cash from operations negative $4.8M.”
“Operating income was negative $10.3M and cash from operations negative $5.4M.”
“Operating income was negative $3.1M and cash from operations negative $2.9M.”
“Operating income was negative $3.8M and cash from operations negative $3.9M.”
“Operating income was negative $3.7M and cash from operations negative $3.1M.”
“Operating income was negative $3.3M and cash from operations negative $2.4M.”
“Operating income was negative $3.0M and cash from operations negative $3.1M.”
Over the trailing year it converted 1.01x of net income into operating cash flow.
Not enough signal yet.
Not enough signal to read sensitivity to real (inflation-adjusted) rates, the broad stock market, long-term interest rates, the US dollar, Fed net liquidity (low R² over the window).
15 material management or governance events in the past 24 months, led by legal/regulatory items. Historically, Health Care names rated volatile grew net income 53% of the time over the next year (vs 50% for the rest of the cohort, n=3986).
Not investment advice. As of 2026-09-04.